Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic Acid ((1s,3r,5r)-8-((r)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl)-8-aza-bicyclo(3.2.1)oct-3-yl)amide
2. Td-5108
3. Td5108
1. Td-5108
2. 866933-46-2
3. J4vnv64arb
4. 1,2-dihydro-n-[(3-endo)-8-[(2r)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide
5. 3-quinolinecarboxamide, 1,2-dihydro-n-((3-endo)-8-((2r)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-methylethyl)-2-oxo-
6. Td 5108
7. Velusetrag [usan]
8. Velusetrag [inn]
9. Unii-j4vnv64arb
10. Velusetrag [usan:inn]
11. Velusetrag [who-dd]
12. Gtpl8425
13. Schembl2917361
14. Chembl2087337
15. Dtxsid001029768
16. Serotonin 5-ht4 Receptor Agonists
17. Bdbm50391069
18. Zinc15821733
19. Compound 15 [pmid 22959244]
20. Db12702
21. Hy-10457
22. Cs-0002610
23. E98885
24. N-((1r,3r,5s)-8-((2r)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8- Azabicyclo(3.2.1)oct-3-yl)-1-(1-methylethyl)-2-oxo-1,2-dihydroquinoline-3-carboxamide
25. N-((1r,3r,5s)-8-((2r)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-methylethyl)-2-oxo-1,2-dihydroquinoline-3-carboxamide
26. N-[(1r,5s)-8-[(2r)-2-hydroxy-3-(methyl-methylsulfonylamino)propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-propan-2-ylquinoline-3-carboxamide
27. N-[(1s,5r)-8-[(2r)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-propan-2-ylquinoline-3-carboxamide
| Molecular Weight | 504.6 g/mol |
|---|---|
| Molecular Formula | C25H36N4O5S |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 504.24064144 g/mol |
| Monoisotopic Mass | 504.24064144 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 932 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Studies demonstrating the in vivo preclinical profile of Velusetrag showed that the compound has potent 5-HT4 receptor agonist activity by several routes of administration, including oral, providing robust prokinetic activity in the digestive tract of three different animal species, consistent with its highly potent and selective 5-HT4 receptor agonist in vitro profile.
Velusetrag is a potent, highly selective agonist with high intrinsic activity at the 5-HT4 receptor. Relative to other 5-HT receptor types, Velusetrag is > 500-fold selective for binding to the human 5-HT4 receptor. Theravance anticipates that the high degree of selectivity of Velusetrag provides the potential for it to be a better and safer medicine for the treatment of patients with severe constipation and possibly constipation predominant irritable bowel syndrome.
ABOUT THIS PAGE
A Velusetrag manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Velusetrag, including repackagers and relabelers. The FDA regulates Velusetrag manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Velusetrag API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Velusetrag supplier is an individual or a company that provides Velusetrag active pharmaceutical ingredient (API) or Velusetrag finished formulations upon request. The Velusetrag suppliers may include Velusetrag API manufacturers, exporters, distributors and traders.
Velusetrag Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Velusetrag GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Velusetrag GMP manufacturer or Velusetrag GMP API supplier for your needs.
A Velusetrag CoA (Certificate of Analysis) is a formal document that attests to Velusetrag's compliance with Velusetrag specifications and serves as a tool for batch-level quality control.
Velusetrag CoA mostly includes findings from lab analyses of a specific batch. For each Velusetrag CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Velusetrag may be tested according to a variety of international standards, such as European Pharmacopoeia (Velusetrag EP), Velusetrag JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Velusetrag USP).
LOOKING FOR A SUPPLIER?
